FDA Releases Guidance on GDUFA Self-Identification
The agency published the guidance to help generic-drug facilities comply with the GDUFA self-identification requirement.
The Generic Drug User Fee Amendments of 2012 (GDUFA) requires generic-drug facilities to annually submit identification information to FDA. On Sept. 22, 2016, FDA released guidance to assist companies with complying with the self-identification requirement.
Self-identification is required to determine the facilities required to pay user fees and to promote global supply chain transparency. The guidance discusses which types of generic facilities, sites, and organizations are required to self-identify; what information is requested; what technical standards are to be used for electronically submitting the requested information; and the penalty for failing to self-identify.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.
